NEW YORK, NY / ACCESSWIRE / June 29, 2017 / 8point3 Energy Partners LP Class A (NASDAQ: CAFD) will be discussing their earnings results in their Q2 Earnings Call to be held June 29, 2017 at 4:30 PM Eastern Time.

To listen to the event live – visit https://www.investornetwork.com/company/24549.

Replay Information

The replay will be available online at https://www.investornetwork.com/company/24549.

About Investor Network

Investor Network (IN) is a new financial content community, serving millions of unique investors market information, earnings, commentary and news on the what’s trending. Dedicated to both the professional and the average traders, IN offers timely, trusted and relevant financial information for virtually every investor. IN is an Issuer Direct brand, to learn more or for the latest financial news and market information, visit www.investornetwork.com. Follow us on Twitter @investornetwork.

SOURCE: Investor Network

ReleaseID: 467126

NEW YORK, NY / ACCESSWIRE / June 29, 2017 / Cinedigm Corp (NASDAQ: CIDM) will be discussing their earnings results in their Q4 Earnings Call to be held June 29, 2017 at 4:30 PM Eastern Time.

To listen to the event live – visit https://www.investornetwork.com/company/23734.

Replay Information

The replay will be available online at https://www.investornetwork.com/company/23734.

About Investor Network

Investor Network (IN) is a new financial content community, serving millions of unique investors market information, earnings, commentary and news on the what’s trending. Dedicated to both the professional and the average traders, IN offers timely, trusted and relevant financial information for virtually every investor. IN is an Issuer Direct brand, to learn more or for the latest financial news and market information, visit www.investornetwork.com. Follow us on Twitter @investornetwork.

SOURCE: Investor Network

ReleaseID: 467127

VANCOUVER, BC / ACCESSWIRE / June 29, 2017 / This notice is being sent to advise that Maple Leaf Short Duration 2016-II Flow-Through Limited Partnership – National Class (CUSIP: 56531T106) and Quebec Class (CUSIP: 56531T205) (the “Partnership”) will be proceeding with a transaction (the “Liquidity Transaction”) pursuant to which the assets of the Partnership (the “Assets”) will be transferred on a tax-deferred basis to the Maple Leaf Resource Class (the “Resource Class Mutual Fund”), a class of shares of Maple Leaf Corporate Funds Ltd., an open-ended mutual fund corporation, in exchange for Series A shares of the Mutual Fund.

Additional information about the Resource Class Mutual Fund is available in their simplified prospectus and annual information form. These documents are available at www.sedar.com and www.mapleleaffunds.ca.

How the Rollover Will Work:

Pursuant to the Liquidity Transaction, Limited Partners of the Partnership (“Investors”) will receive shares of the Resource Class Mutual Fund in connection with the dissolution of the Partnership. The effective date of the Liquidity Transaction (the “Effective Date”) is expected to be on or about September 8, 2017. Shortly after the Effective Date, the shares of the Resource Class Mutual Fund will be distributed on a pro rata basis to investors and thereafter the Partnership will be dissolved.

Investors will receive the Resource Class Mutual Fund shares in exchange for, and with a value equal to, the value of the units of the Partnership held at the time of such transfer of Assets. When the shares of the Resource Class Mutual Fund are received, the Partnership units will be removed from each Investors account. Processing may take 2 to 3 business days (in some cases longer) to complete, after the rollover occurs.

Once the Liquidity Transaction is completed, Investors can elect to hold or redeem their Resource Class shares; contribute them shares to an RRSP, RRIF, RESP, DPSP, RDSP, or TFSA; or switch their investment into the Maple Leaf Income Class (the “Income Class Mutual Fund”). The Income Class Mutual Fund holds a diversified portfolio of blue chip stocks that offer a combination of growth and income with a mandate to generate stable returns. The 1 year return for the Income Class Mutual Fund for the period ending May 31, 2017 was +14.25%. The Income Class Mutual Fund has been rated FundGrade™ A from Fundata in recognition of outstanding performance for the period ending May 31, 2017.

The Partnership will issue a press release once Liquidity Transaction has been completed and the conversion ratio has been determined.

The ACB (adjusted cost base) for each unit of the Partnership and each share of the Resource Class Mutual Fund will be determined by the General Partner upon the wind-up of the Partnership’s affairs. The Partnership will dissolve within 60 days of the Effective Date. The General Partner will post these details on its website at www.mapleleaffunds.ca.

Investors should consult with their investment advisor and/or tax advisor for all tax-related matters.

Simplified Example:

An Investor holds 100 Partnership units with a final Net Asset Value of $20.00 at the time of rollover and the net asset value per share of the Resource Class Mutual Fund is $10.00 on the same date. Based on these net asset values, the conversion ratio will be 2.0 (2.0 = $20.00 / $10.00). The Partner’s 100 units, valued at $2,000, are removed from the limited partner’s account and 200 shares (200 = 100 x 2.0) of the Resource Class Mutual Fund, valued at $2,000, are added to the Investor’s account.

Processing can be delayed after the rollover occurs, therefore transactions such as switches or redemptions may not be processed until the Resource Class Mutual Fund shares have been credited to client accounts.

Neither the Partnership nor the Resource Class Mutual Fund will accept any liability for transactions in executed prior to dealer records being updated.

Specific Information about the Mutual Fund:

Organization
and Management of the Mutual Fund

Manager:
CADO Investment Fund Management Inc.
609 Granville Street, Suite 808
Vancouver, BC V7Y 1G5
Tel: 604-684-5742
Fax: 604-684-5748
Email: info@cadobancorp.ca

CADO Investment Fund Management Inc.is the manager of the Mutual Fund and is responsible for managing he overall business and operations of the Mutual Fund.

Portfolio Advisor:

T.I.P. Wealth Manager Inc. (“TIP”)

Toronto, ON

T.I.P. Wealth Manager Inc. is responsible for managing the investment portfolio of the Funds.

Custodian:

RBC Investor Services Trust

Toronto, ON

The custodian has physical custody of the Mutual Fund’s property.

Administrator:

IAS Investment Administration Solution Inc. (“IAS”)

Toronto, ON

The administrator keeps track of the owners of shares of the Mutual Fund and processes purchases.

Auditor:
KPMG LLP
Vancouver, BC

The auditors are responsible for auditing the annual financial statements of the Mutual Fund.

The auditors of the Mutual Fund may not be changed unless the independent review committee of the Mutual Fund has approved the change and a written notice describing the change is sent to unit holders at least 60 days before the effective date of the change.

Independent Review Committee
(the “IRC”)

Canadian securities legislation requires the Mutual Fund to have an IRC. The IRC is composed of three members, each of whom is independent of us. The mandate of the IRC is to review, and provide input on, our written policies and procedures that deal with conflict of interest matters in respect of the Mutual Fund and to give their recommendation regarding and, in some cases, approve, conflict of interest matters identified and referred to the IRC by us.

The IRC will prepare, at least annually, a report of its activities for investors. This report will be available at our website at www.mapleleaffunds.ca or you may request a copy, at no cost to you, by contacting us at info@cadobancorp.ca. Additional information about the IRC, including the names of the members, is available in the Mutual Fund’s Annual Information Form.

Portfolio Advisor:

T.I.P. Wealth Manager Inc. (“T.I.P.”) will be responsible for the Mutual Fund’s investment activities. Mr. Jim Huang, President of T.I.P., will act as Portfolio Manager on behalf of TIP. Mr. Huang has over 20 years of experience investing in the Canadian capital markets. As lead or co-manager while working at NATCAN (formerly Altamira), Mr. Huang has managed or co-managed over $2 billion in mutual funds and institutional assets, including all of the resource and equity income products in the Altamira and National Bank mutual fund families. Altamira Energy Fund, Altamira Resource Fund, Altamira Precious and Strategic Metals Fund and AltaFund (a Canadian Equity fund focusing on Western Canada) had industry-leading performance and won awards and positive press coverage during Mr. Huang’s management. Currently, Mr. Huang is the manager for the T.I.P. Opportunities Fund, a long/short North American equity hedge fund, as well as being the lead manager for the Maple Leaf Short Duration Flow-Through Funds, the Maple Leaf Corporate Funds Ltd. family of mutual funds and a small cap equity mutual fund. Mr. Huang has also been awarded a FundGrade™ A rating from Fundata in recognition for the outstanding performance of Maple leaf Income Class Mutual Fund.

Additional Information:

Additional information about the Mutual Fund will be available in the Mutual Fund’s simplified prospectus, annual information form, management reports of fund performance and financial statements. You can obtain a copy of these documents at your request and at no cost by contacting Maple Leaf Funds toll free at 1-866-688-5750, by e-mailing info@maplelelaffunds.ca, by download from www.mapleleaffunds.ca, or from your financial advisor.

Other information about the Mutual Fund is available at SEDAR (the System for Electronic Document Analysis and Retrieval established by the Canadian Securities Administrators) at www.sedar.com.

For further information or assistance with respect to the Mutual Fund or the Limited Partnership, please contact:

CADO Investment Fund Management Inc.

609 Granville Street, Suite 808, Vancouver, BC V7Y 1G5
Tel: 604-684-5742 | Toll Free: 866-688-5750 | Fax: 604-684-5748
Email: info@cadobancorp.ca | Web: www.mapleaffunds.ca

SOURCE: Maple Leaf Corporate Funds Ltd.

ReleaseID: 467164

WEST PALM BEACH, FL / ACCESSWIRE / June 29, 2017 / Steve Nudelberg, Principal Thinker of On the Ball Ventures, is pleased to announce the partnership between John Salley and Stem Cell Centers of Excellence.

On June 24, 2017, John Salley had his first stem cell procedure to harvest his own stem cells and create relief in his shoulders and knees. On the Ball, in keeping with our mantra to create ideas and opportunities to grow business, felt that John Salley would be a natural addition to enhance the national roll out of Stem Cell Centers of Excellence treatment clinics. “As a spokesperson for the vegan lifestyle and long-time friend of On the Ball, John has a keen understanding of how the body functions and how stem cell treatment is a natural alternative for the athlete community. John is a perfect conduit,” says Steve Nudelberg

John Salley, Entrepreneur, NBA Star, Actor, Philanthropist, and Vegan, has suffered years of agonizing pain after a lucrative career in the NBA. He was set to have surgery on his knees and shoulders but, in keeping with his vegan, clean philosophy, Salley partnered with Stem Cell Centers of Excellence to advocate for using your own body’s stem cells to heal itself. “I am excited to be part of the future with the team at Stem Cell Centers of Excellence. Two things jump to mind after my recent treatment: one, I can’t wait for my body to start healing itself and, two, I feel secure in knowing that my stem cells, which are not getting any younger, are now stored and will be ready should I need them for future use at any time,” says John Salley.

“Superstar athlete and wellness expert John Salley is the ideal individual to represent Stem Cell Centers of Excellence as we continue educating the public about the benefits of stem cells and the body’s ability to heal itself,” said Mike Tomas, President and CEO of U.S. Stem Cell Inc. “John has seen first-hand how injuries to athletes, and sports enthusiasts alike, can be devastating with long recovery times. Cutting-edge stem cell treatments for individuals with orthopedic as well as neurological conditions are an excellent option for these patients to improve their quality of life.”

With a new clinic in Miami, FL and additional clinics opening soon around the country, Stem Cell COE provides comprehensive stem cell treatments using the U.S. Stem Cell Inc. (OTCQB: USRM) innovative technologies and the latest USSC regenerative medicine research. After treatment, the body’s own healing potential may naturally repair and regenerate damaged tissue. U.S. Stem Cell’s team of scientists have pioneered in-clinic regenerative medicine protocols and helped thousands of patients to naturally heal. The company is at the forefront of this innovative technology and will continue to create unique solutions for patients in need. For more information or to make an appointment, visit www.stemcellcoe.com.

On the Ball has been in business for over twenty-two years. Starting out as a sports marketing company to a traditional marketing agency to business development resource. Acclaimed for its strategic thinking and sales-focused abilities, On the Ball specializes in all things sales. By investing time and talent in emerging ideas, the agency can specifically help companies grow.

About U.S. Stem Cell, Inc.

US Stem Cell, Inc. (formerly Bioheart, Inc.) is an emerging enterprise in the regenerative medicine / cellular therapy industry. We are focused on the discovery, development and commercialization of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. We believe that regenerative medicine / cellular therapeutics will play a large role in positively changing the natural history of diseases ultimately, we contend, lessening patient burdens as well as reducing the associated economic impact disease imposes upon modern society.

Our business, which includes three operating divisions (US Stem Cell Training, Vetbiologics, and US Stem Cell Clinic), includes the development of proprietary cell therapy products, as well as revenue generating physician and patient based regenerative medicine / cell therapy training services, cell collection, and cell storage services, the sale of cell collection and treatment kits for humans and animals, and the operation of a cell therapy clinic. Management maintains that revenues and their associated cash in-flows generated from our businesses will, over time, provide funds to support our clinical development activities as they do today for our general business operations. We believe the combination of our own therapeutics pipeline combined with our revenue generating capabilities provides the Company with a unique opportunity for growth and a pathway to profitability.

Forward-Looking Statements:

Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may,” “will,” “to,” “plan,” “expect,” “believe,” “anticipate,” “intend,” “could,” “would,” “estimate,” or “continue,” or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

The Company is subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled “Risk Factors” in its Annual Report on Form 10-K for the year ended December 31, 2016, and its Quarterly Reports on Form 10-Q.

Contact:

Aziel Shea
shea@ontheballmarketing.com
(561) 596-9402

SOURCE: U.S. Stem Cell, Inc.

ReleaseID: 467163

IRVINE, CA / ACCESSWIRE / June 29, 2017 / Khang & Khang LLP (the “Firm”) announces a securities class action lawsuit against ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular” or the “Company”) (NYSE MKT: IMUC). Investors, who purchased or otherwise acquired shares from May 1, 2012 through December 11, 2013, inclusive (the “Class Period”), are encouraged to contact the Firm by the June 30, 2017 lead plaintiff motion deadline.

If you purchased ImmunoCellular shares during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone at (949) 419-3834, or by e-mail at joon@khanglaw.com.

There has been no class certification in this case yet. Until certification occurs, you are not represented by an attorney. You may also choose to take no action and remain a passive class member.

According to the Complaint, during the Class Period, ImmunoCellular issued materially false and/or misleading statements and/or failed to disclose: that the Company retained Lidingo Holdings, LLC to publish promotional articles designed to unlawfully promote the Company; and that the market was led to believe that ImmunoCellular’s clinical studies for its product candidate, ICT-107, were going well, which artificially inflated the stock price. When this news was released, ImmunoCellular’s stock price dropped materially, which harmed investors according to the Complaint. On April 10, 2017, the SEC announced enforcement actions against several individuals and entities, including ImmunoCellular, that engaged in stock promotion schemes.

If you wish to learn more about this lawsuit, or if you have any questions about this notice or your rights, please contact Joon M. Khang, Esquire, a prominent litigator for nearly two decades, by telephone at (949) 419-3834, or by e-mail at joon@khanglaw.com.

This press release may be considered Attorney Advertising in some jurisdictions.

Contact:

Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 467161

VANCOUVER, BC / ACCESSWIRE / June 29, 2017 / CopperBank Resources Corp. (“CopperBank”) (CSE: CBK) (OTC PINK: CPPKF) is pleased to announce that the Company has completed a non-brokered private placement of 4,166,667 common shares at a price of $0.12 per share for a total of $500,000. No commissions were paid in this financing.

The private placement is subject to the approval of the Canadian Securities Exchange and the securities will be subject to a four month and one day hold period under securities laws.

The Company intends to use the net proceeds from the private placement for advancing its projects and for general working capital and corporate purposes.

The Company also announces that a total of CDN $93,000 owed to company management has been settled in common shares in the company at a deemed price of 0.12 per share. A total of 775,000 shares will be issued to settle this amount and will have a four month hold from date of issuance. The convertible loan and shares for debt arrangements are subject to Canadian Securities Exchange approvals and policies.

On behalf of CopperBank Resources Corp.

“Gianni Kovacevic”
Executive Chairman

Address: Suite 1500, 409 Granville Street, Vancouver, BC V6C 1T2
Tel: 604-889-0852
E-mail: gk@copperbankcorp.com
Website: www.copperbankcorp.com

Advisory Regarding Forward-Looking Statements

Certain information in this release constitutes forward-looking statements or information (“forward-looking statements”) under applicable securities laws and necessarily involves risks and uncertainties. Forward-looking statements included herein are made as of the date of this news release and, except as required by applicable law, CopperBank does not undertake any obligation to update or revise any of the forward-looking statements, whether as a result of new information, future events or otherwise. The forward-looking statements contained in this document are expressly qualified by this cautionary statement. Forward-looking statements relate to future events or future performance and reflects management of CopperBank’s expectations or beliefs regarding future events. In certain cases, forward-looking statements can be identified by the use of words such as “plans”, or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved” or the negative of these terms or comparable terminology. Examples of forward-looking statements in this news release include, but are not limited to, statements with respect to the Company’s ongoing review of its existing portfolio, the involvement of CopperBank in any potential divestiture, spin-out, partnership or other transactions involving the Company’s portfolio assets, and the ability of the Company to complete any such transactions, the ability of CopperBank to enter into transactions that will ultimately enhance shareholder value, and potential future work or activities in respect of the Pyramid project or the Contact project. Although CopperBank believes that the expectations reflected in the forward-looking statements are reasonable, forward-looking statements have been based on factors and assumptions concerning future events which may prove to be inaccurate. Those factors and assumptions are based upon currently available information available to CopperBank. Forward-looking statements are based, in part, on assumptions and factors that may change or prove to be incorrect, thus causing actual results, performance or achievements to be materially different from those expressed or implied by forward-looking information. Such factors and assumptions include, but are not limited to, the Company’s ability to identify and complete one or more transactions involving the Company’s portfolio assets that enhance shareholder value as part of management’s ongoing review of strategic alternatives in the current market conditions. By their very nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by forward-looking statements. Such factors include, but are not limited to, the risk that the Company will not be able to identify and complete one or more transactions involving the Company’s portfolio assets that enhance shareholder value as part of management’s ongoing review of strategic alternatives in the current market conditions. Although CopperBank has attempted to identify important factors that could cause actual actions, events or results to differ materially from forward-looking statements, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated by such forward-looking statements. Accordingly, readers should not place undue reliance on forward-looking statements. For more information on CopperBank and the risks and challenges of its businesses, investors should review the continuous disclosure filings that are available under CopperBank’s profile at www.sedar.com.

SOURCE: CopperBank Resources Corp.

ReleaseID: 467052

NEW YORK, NY / ACCESSWIRE / June 29, 2017 / Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a boutique securities firm headquartered at the Empire State Building in New York City, announces that a class action lawsuit has been filed in United States District Court for the Central District of California against ImmunoCellular Therapeutics (NYSE MKT: IMUC) (“ImmunoCellular Therapeutics” or the “Company”) on behalf of purchasers of the Company’s securities between May 1, 2012 and December 11, 2013, inclusive (the “Class Period”).

The lawsuit is based on whether ImmunoCellular Therapeutics and its executives violated federal securities law by issuing false and/or misleading statements that ImmunoCellular retained Lidingo Holdings, LLC to publish articles designed to unlawfully promote the Company. Investors were led to believe that the Company’s clinical studies for its lead product candidate, ICT-107, were going well in order to inflate ImmunoCellular’s share price.

After market close on December 11, 2013, the Company revealed that the primary endpoint for its ICT-107 Phase II study “did not reach statistical significance” because it failed to increase overall survival in patients diagnosed with glioblastoma multiforme. When the information was revealed to the public, the value of ImmunoCellular stock dropped, causing losses to its shareholders.

Mr. Monteverde would like to personally discuss with you how to potentially recover your monetary losses, if incurred during the Class Period.

If you wish to serve as lead plaintiff, you must move the Court no later than June 30, 2017. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.

Click here for more information: http://monteverdelaw.com/securities/. It is free and there is no cost or obligation to you.

Monteverde & Associates PC is a boutique class action securities and consumer litigation law firm committed that has recovered millions of dollars and is committed to protecting shareholders and consumers from corporate wrongdoing. Monteverde & Associates PC lawyers have significant experience litigating Mergers & Acquisitions and Securities Class Actions, whereby they protect investors by recovering money and remedying corporate misconduct.

Contact:

Juan E. Monteverde, Esq.
MONTEVERDE & ASSOCIATES PC
The Empire State Building
350 Fifth Ave, Suite 4405
New York, NY 10118
United States of America
jmonteverde@monteverdelaw.com
Tel: (212) 971-1341

Attorney Advertising. (C) 2017 Monteverde & Associates PC. Prior results do not guarantee a similar outcome with respect to any future matter.

SOURCE: Monteverde & Associates PC

ReleaseID: 467160

TEL AVIV, ISRAEL / ACCESSWIRE / June 29, 2017 / Elbit Imaging Ltd. (“EI” or the “Company”) (TASE, NASDAQ: EMITF) announced today, that On June 28, 2017, following approval by the audit committee and board of directors of the Company, the Company and Brightman Almagor Zohar & Co., a Member Firm of Deloitte Touche Tohmatsu (the “Former Auditor”), reached an understanding to end the engagement of the Former Auditor as the independent accountants of the Company effective immediately.

This understanding resulted from the previously announced notification by the Company’s Former Auditor that it was unable to provide an unqualified audit opinion regarding the Company’s financial statements for 2016 as a result of matters underlying the disclaimer made by KPMG Hungaria Kft., the former auditor of Plaza Centers N.V. (“Plaza”) (LSE: PLAZ), an indirect subsidiary (45%) of the Company, in its report relating to Plaza’s annual financial statements for 2016, which report expresses no opinion with regard to Plaza’s financial statements.

In addition, on June 28, 2017, following approval by the audit committee and board of directors of the Company, the Company approved the engagement with KOST FORER GABBAY & KASIERER (A Member of EY Global) (“EY Israel”) as the Company’s new independent Auditor, subject to shareholders’ approval. EY Israel has also been retained by Plaza to serve as the independent accountants of Plaza.

About Elbit Imaging Ltd.

Elbit Imaging Ltd. operates in the following principal fields of business: (i) Commercial centers – initiation, construction, and sale of commercial centers and other mixed-use property projects, predominantly in the retail sector, located in Central and Eastern Europe. In certain circumstances and depending on market conditions, the Group operates and manages commercial centers prior to their sale. (ii) Hotel – operation and management of the Radisson hotel Complex in Bucharest, Romania. (iii) Medical industries and devices – (a) research and development, production and marketing of magnetic resonance imaging guided focused ultrasound treatment equipment, and (b) development of stem cell population expansion technologies and stem cell therapy products for transplantation and regenerative medicine. (iv) Plots in India – plots designated for sale initially designated to residential projects.

Any forward-looking statements in our releases include statements regarding the intent, belief or current expectations of Elbit Imaging Ltd. and our management about our business, financial condition, results of operations, and its relationship with its employees and the condition of our properties. Words such as “believe,” “expect,” “intend,” “estimate,” and similar expressions are intended to identify forward-looking statements but are not the exclusive means of identifying such statements. Actual results may differ materially from those projected, expressed or implied in the forward-looking statements as a result of various factors including, without limitation, a change in market conditions, a decision to deploy the cash for other business opportunities and the factors set forth in our filings with the Securities and Exchange Commission including, without limitation, Item 3.D of our annual report on Form 20-F for the fiscal year ended December 31, 2015, under the caption “Risk Factors.” Any forward-looking statements contained in our releases speak only as of the date of such release, and we caution existing and prospective investors not to place undue reliance on such statements. Such forward-looking statements do not purport to be predictions of future events or circumstances, and therefore, there can be no assurance that any forward-looking statement contained in our releases will prove to be accurate. We undertake no obligation to update or revise any forward-looking statements.

For Further Information:

Company Contact
Ron Hadassi
Chairman of the Board of Directors
Tel: +972-3-608-6048
Fax: +972-3-608-6050
ron@elbitimaging.com

SOURCE: Elbit Imaging Ltd.

ReleaseID: 467156